Protecting Personnel During Nuclear Decommissioning

Radiation safety protocols at the Fukushima Daiichi Nuclear Power Station (FDNPS) are evolving as decommissioning enters a critical phase. While decontamination efforts have allowed standard clothing in 96% of the site, reactor buildings remain high-risk zones. Therefore, implementing advanced internal radiation exposure monitoring is crucial for worker protection during the upcoming removal of fuel debris. This process requires a shift from general screening to detailed individual dose assessments.

The primary challenge in these special operations involves managing both alpha-emitting and gamma-emitting radionuclides. Currently, Cs-137 is the dominant radionuclide requiring individual monitoring for all workers entering controlled areas. To address this, TEPCO employs whole-body counters for initial screening. However, as 2024 approaches, the nature of workplace hazards is expected to change due to direct contact with fuel debris.

Advancing Internal Radiation Exposure Monitoring Techniques

As work shifts deeper into reactor buildings, simple screening is no longer sufficient. Consequently, a comprehensive monitoring system must integrate both in-vivo and in-vitro bioassays. This hybrid approach allows for the precise calculation of specific radionuclides that contribute to the internal dose during exposure events. Furthermore, quality assurance programs are being updated to ensure the high reliability of individual monitoring data as operational complexity increases.

Decommissioning activities from 2024 onwards will involve handling melted nuclear fuel debris, which increases the risk of inhaling or ingesting unsealed radioactive materials. This phase necessitates more frequent in-vitro bioassays, such as urine or fecal analysis, to detect less volatile isotopes. Moreover, workplace measurement data from FDNPS currently guides the selection of appropriate monitoring frequencies. This data-driven strategy minimizes health risks while allowing steady progress in site restoration.

Frequently Asked Questions

What is the difference between in-vivo and in-vitro bioassays?

In-vivo bioassays involve the direct measurement of radiation from the body using devices like whole-body counters. In contrast, in-vitro bioassays analyze biological samples, such as urine or excreta, to detect specific radionuclides that have been internalized.

Why is Cs-137 the focus of monitoring at FDNPS?

Cs-137 is currently the most prevalent radionuclide at the site and emits gamma radiation, which is easily detected via whole-body counting. It serves as a primary indicator of potential internal exposure for workers operating in controlled areas.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or establish a doctor-patient relationship. Refer to the latest local and national guidelines for clinical practice.

References

1. Ohno M et al. Individual monitoring for internal exposure of workers in fdnps. Ann ICRP. 2026 May 13. doi: 10.1177/01466453251412151. PMID: 42125874.


2. International Atomic Energy Agency. Corroboration of Internal Exposure Monitoring for Workers at Fukushima Daiichi. IAEA Report. 2024.


3. International Commission on Radiological Protection. Occupational Intakes of Radionuclides: Part 1. ICRP Publication 130. Ann. ICRP 44(2).